share_log

派林生物(000403.SZ):静注人免疫球蛋白(10%)获准开展临床试验

Pailin Biotech (000403.SZ): Intravenous human immunoglobulin (10%) approved for clinical trials

Zhitong Finance ·  May 22 06:30

Zhitong Finance App News, Pailin Biotech (000403.SZ) announced that Guangdong Shuanglin Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The name of the relevant drug is intravenous human immunoglobulin (10%), and it has agreed to carry out clinical trials with primary immune thrombocytopenia as the indication.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment